Singapore Paincare has reported a remarkable 90% relief rate for seniors suffering from chronic pain, thanks to its proprietary Painostic® diagnostic model. Between 2020 and 2024, the model has provided meaningful relief after just one minimally invasive procedure, reducing the need for long-term medication or surgery. This breakthrough is particularly significant as Singapore’s ageing population continues to grow, increasing the demand for effective pain management solutions.
The Painostic® model integrates precision diagnostics with targeted interventions, including Myospan and Neurospan treatments, and is complemented by rehabilitation and Traditional Chinese Medicine. This holistic approach has been pivotal in achieving high success rates, as noted by Bernard Lee, Founder and CEO of Singapore Paincare. With over 25 years of clinical experience, Lee was inspired to develop these treatments after witnessing his father’s struggle with cancer-related pain.
The success of Singapore Paincare’s approach highlights the potential of combining Western medical practices with Traditional Chinese Medicine to manage chronic pain effectively. The company has treated over 3,000 patients, demonstrating the real-world impact of its methods.
Looking ahead, Singapore Paincare aims to continue refining its techniques and expanding its reach to provide relief to more patients. The integration of innovative diagnostic models like Painostic® could set a new standard in pain management, offering hope to those suffering from chronic conditions.
“`
